EPISODE · Dec 16, 2017 · 33 MIN
Superblood: The Development of Novel Red-Cell Therapeutics
from The Onco'Zine Brief with Peter Hofland · host Peter Hofland
In an Interview with Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, David R. Epstein BSc, MBA, the Executive Chairman of Rubius Therapeutics, explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases. Epstein explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
What this episode covers
In an Interview with Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, David R. Epstein BSc, MBA, the Executive Chairman of Rubius Therapeutics, explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases. Epstein explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
NOW PLAYING
Superblood: The Development of Novel Red-Cell Therapeutics
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m